A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia

Expert Review of Neurotherapeutics

Volumn 7, Issue 11, 2007, Pages 1457-1463

  Cummings, Jeffrey ^a   Winblad, Bengt ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Patch; Rivastigmine; Transdermal

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DEMENTIA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE TRACKING; HUMAN; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; NAUSEA; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PSYCHOLOGIC TEST; REVIEW; SIDE EFFECT; SKIN IRRITATION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

ALZHEIMER DISEASE; DEMENTIA; HUMANS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PHENYLCARBAMATES;

EID: 36148947831     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.11.1457     Document Type: Review

References (26)

1. Fratiglioni L, Launer LJ, Andersen K et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S10-S15 (2000).
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 60, 387-392 (2003).
3. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1154-1166 (2001).
4. Wallin AK, Andreasen N, Eriksson S et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement. Geriatr. Cogn. Disord. 23, 150-160 (2007).
5. Fitzpatrick AL, Kuller LH, Lopez OL, Kawas CH, Jagust W. Survival following dementia onset: Alzheimer's disease and vascular dementia. J. Neurol. Sci. 229-230, 43-49 (2005).
6. Singh G, Thomas SK, Arcona S, Lingala V, Mithal A. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J. Am. Geriatr. Soc. 53, 1269-1270 (2005).
7. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alzheimer Dis. Assoc. Disord. 16, 49-51 (2002).
8. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: can a transdermal patch offer a solution? Curr. Med. Res. Opin. 23, 2705-2713 (2007).
9. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst. Rev. 1, CD005593 (2006).
10. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509-2518 (2004). •• Primary results of the rivastigmine study forming the basis of its approval in Parkinson's disease dementia patients.
11. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int. J. Geriatr. Psychopharmacol. 1, S26-S34 (1998).
12. Doraiswamy PM, Krishnan KR, Anand R et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits? Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 705-712 (2002).
13. Finkel SI. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin. Ther. 26, 980-990 (2004).
14. Mercier F, Lefèvre G, Huang AH-L, Schmidli H, Amzal B, Appel-Dingmanse S. Rivastigmine exposure provided by a transdermal patch versus capsule. Curr. Med. Res. Opin. (2007) (Epub ahead of print).
15. Darreh-Shori T, Almkvist O, Guan ZZ et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 59, 563-572 (2002).
16. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J. Neural Transm. 109, 1053-1065 (2002).
17. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging 13, 391-411 (1998).
18. Feldman HH, Lane R. Rivastigmine: A placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 78(10), 1056-1063 (2007).
19. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 15, 375-390 (2001).
20. Lefèvre G, Sedek G, Huang HL et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J. Clin. Pharmacol. 47, 471-478 (2007).
21. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 22, 456-467 (2007). •• Primary results of the Investigation of Transdermal Exelon in Alzheimer's Disease study.
22. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 23, 357-375 (2006).
23. Cevc G. Drug delivery across the skin. Expert Opin. Investig. Drugs 6, 1887-1937 (1997).
24. Nitti VW, Sanders S, Staskin DR et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 67, 657-664 (2006). • Comprehensive review of transdermal patch technology.
25. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 20, 1512-1517 (1997).
26. Lefèvre G, Sedek G, Jhee S et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin. Pharm. Ther. DOI:10.1038/sj.clpt.6100242 (2007) (Epub ahead of print). • Primary results of a pharmacokinetic study of the rivastigmine patch.